Unlocking Cures: How the Private Sector is Shaping Access to Gene Therapies for Inherited Retinal Diseases
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), the promise of cell and gene therapies offers profound hope. These groundbreaking treatments are revolutionizing medicine, moving beyond managing symptoms to addressing the root causes of disease. However, ensuring these life-changing therapies are accessible and affordable remains a critical hurdle. A recent article in Health Affairs, published on August 13, 2025, titled "A Private Sector Approach To Cell And Gene Therapy In The US," sheds light on how the private sector is grappling with these complex issues, which directly impacts the IRD community.
Cell and gene therapies (CGTs) have emerged as transformative solutions for diseases once considered untreatable, holding the potential for longer, healthier, and more productive lives. For the IRD community, where many conditions are caused by specific gene mutations, gene therapies represent a paradigm shift from chronic management to potential cures. The article highlights that these therapies can offer significant improvements in patient outcomes and may even lead to long-term medical cost reductions by averting decades of costly, chronic care.
However, the path to access is not without its challenges. The Health Affairs article points out that while CGTs are transformative, they create new uncertainties regarding affordability, access, and the stability of health insurance systems that were not designed for them. The high costs of production and delivery, coupled with prices often exceeding $2 million to $3 million per treatment, present significant barriers. The fragmentation of the U.S. health care financing system further complicates matters. According to the article, a piecemeal approach to individual CGTs is likely to remain burdensome and have limited impact.
For patients and families affected by IRDs, this means that while scientific breakthroughs are bringing cures closer, the financial and systemic aspects of healthcare delivery are still catching up. The article emphasizes the need for a more holistic solution that integrates steps to address these cross-cutting challenges, aiming to advance access to effective gene therapies in a robust and sustainable market. This requires a collaborative effort from the U.S. private sector, including payers, providers, purchasers, and patients, to rethink how to manage risk and align incentives. The goal is to achieve broader access and long-term value while better managing short-term costs.
The authors of the Health Affairs article, William H. Shrank, Steven D. Pearson, and Mark B. McClellan, suggest that feasible actions can encourage broader private-sector collaborative efforts to achieve more comprehensive solutions. By tackling these challenges head-on and engaging all key stakeholders, the full potential of these transformative therapies can be unlocked, laying the foundation for a healthcare system that prioritizes cures over chronic management. The stakes are high, but the opportunity to fundamentally improve lives and reduce long-term healthcare costs makes this a challenge worth tackling.
This ongoing dialogue within the private sector is crucial for the IRD community, as it directly influences how soon and how widely these innovative treatments will be available. As more gene therapies for IRDs progress through clinical trials and seek approval, the frameworks being discussed now will determine the future landscape of patient access.